Data Collection

Data Collection


Time filter

Source Type

BOCA RATON, Fla.--(BUSINESS WIRE)--Specialty-specific health information technology leader, Modernizing Medicine, Inc., will present the latest solutions in its award-winning electronic health record (EHR) system to address value-based care and improve physician efficiency at the Association of Dermatology Administrators & Managers (ADAM) Annual Meeting and the American Academy of Dermatology (AAD) Annual Meeting this week. The company recently announced that EMA™, the mobile EHR system in the modmed Dermatology™ suite, is among the first in the United States to include built-in Merit-based Incentive Payment System (MIPS) intelligence, including composite score reporting, robust analytics and benchmarking reports that document healthcare providers’ performance in near real-time. The automated solution is currently available and was designed to help clients exceed the minimum threshold or achieve exceptional performance with MIPS in 2017. “In the new age of MIPS and value-based care, it's critical to have the right healthcare technology to help find the balance of driving better outcomes while reducing the administrative burden on physicians and their staff,” said Dr. Michael Sherling, CMO and co-founder of Modernizing Medicine. “Several strategies exist to help dermatologists, including collecting structured patient information during the exam to reduce data entry, interoperability and providing transparency and visibility for value-based reimbursement. If your systems don’t support these strategies, then you’re probably spending too much time documenting, not enough time on quality patient interactions and not being fully reimbursed for your services.” Dr. Sherling is scheduled to present strategies to address MIPS at this year’s ADAM conference on Tuesday, February 28, from 4:10 – 5:10 p.m. at the Loews Royal Pacific Resort in Orlando, Fla. At ADAM and AAD, Modernizing Medicine will showcase the mobile, touch and cloud-based modmed Dermatology™ suite of products and services designed to help drive value-based decisions, promote quality care and reduce healthcare costs. The dermatology-specific suite includes EMA; Practice Management; Revenue Cycle Management; modmed Telehealth™; Pathology; Specialized Registries; and Analytics, including the Clinical Performance Activities Module which provides metrics dashboards to further help physicians track and improve the quantity and quality of referrals and find revenue gaps. Modernizing Medicine will also introduce the Patient Kiosk, a platform built to speed up the check-in process by letting patients update their personal information and medical history and sign consent forms on an iPad. Kiosk integrates with EMA to add data to the patient’s record automatically. In addition, Modernizing Medicine and AAD are collaborating on a DataDerm registry pilot for 2017. EMA users who participate in the pilot will receive the following benefits: "Clinical data is needed from all dermatologists to benefit the specialty. AAD is pleased that Modernizing Medicine is now offering the option for their users to contribute to DataDerm," shares Marta J. Van Beek, MD, MPH, FAAD, Assistant Secretary-Treasurer of AAD, and Chair of AAD's Ad Hoc Task Force on Data Collection. Dr. Sherling adds, “Modernizing Medicine welcomes the opportunity to work with DataDerm and we feel that dermatologists and their patients across the United States will benefit from the collaboration.” Used by over 35 percent of U.S. dermatologists, EMA has been named the #1 EHR system for three consecutive years by Black Book Market Research and the top ranked system for dermatologists in the inaugural KLAS® Ambulatory Specialty 2016 One Size Does Not Fit All Performance Report. Attendees at the upcoming dermatology conferences can learn more about modmed Dermatology at booth #19 at ADAM from Feb. 27 to March 1 and #2665 at AAD from March 3 to 5 during exhibit hours. For more information about the events, please visit the Association of Dermatology Administrators & Managers here and the American Academy of Dermatology here. Modernizing Medicine® and its affiliated companies empower physicians with suites of mobile, specialty-specific solutions that transform how healthcare information is created, consumed and utilized to increase efficiency and improve outcomes. Built for value-based healthcare, Modernizing Medicine’s data-driven, touch- and cloud-based products and services are programmed by a team that includes practicing physicians to meet the unique needs of dermatology, gastroenterology, ophthalmology, orthopedics, otolaryngology, pain management, plastic surgery, rheumatology and urology practices, as well as ambulatory surgery centers. For more information, please visit www.modmed.com. Connect with Modernizing Medicine on our Blog, Facebook, LinkedIn and Twitter. Modernizing Medicine is a member of CommonWell Health Alliance.* *‘CommonWell Health Alliance’ and the CommonWell logo are licensed trademarks of CommonWell Health Alliance in the U.S. and other jurisdictions.


June 1, 2017 Webinar: Co-Developers of PRAPARE Social Health Determinants Tool on SDOH Data Collection and Response in Primary Care AllianceChicago, a co-developer of the PRAPARE tool to assess social determinants of health (SDOH), will share its experiences in collecting and analyzing SDOH data from 38 FQHCs to improve individual and population-based care. Sea Girt, NJ, May 22, 2017 --( During "Assessing Social Determinants of Health: Collecting and Responding to Data in the Primary Care Setting," a June 1, 2017 webinar at 1:30 p.m. Eastern, AllianceChicago will share key learnings from PRAPARE deployment and SDOH collection. Following this 45-minute live webcast, this Healthcare Intelligence Network program will be available in on-demand and recorded formats for educational and training purposes. Learn more about collecting and assessing social determinants of health data in the primary care setting at http://store.hin.com/product.asp?itemid=5231 News Facts: Scheduled Speaker: Andrew Hamilton, RN, BSN, MS, chief informatics officer/deputy director, AllianceChicago. Conference Focus: The key details from AllianceChicago's PRAPARE deployment that addresses each FQHC's patient population, in-house staff and resources and community support. Mr. Hamilton will cover the following: - How organizations are collecting SDOH data...from assessment administration format to the timing and care team members participating in the collection—as well as the challenges, data collected and opportunities from various scenarios; - Prerequisite resources for healthcare providers embarking upon SDOH data collection; - Why staff training and buy-in is a critical aspect of SDOH data collection and the key training components; - How healthcare providers can react to SDOH data, including community resource referrals, healthcare action prescriptions, inclusion in longitudinal care plans and management of population health; - What technology is required to store and track SDOH data; and - The correlation of SDOH data collection and action on Hemoglobin A1C levels and asthma and blood pressure control. Ample time for Q&A will be provided. Webinar Formats: 45-minute live webinar on June 1, 2017 at 1:30 pm Eastern, including Q&A; "On-Demand" replay available June 2, 2017; 45-minute training DVD or CD-ROM with printed transcript available June 22, 2017. Participants may add an on-demand replay, DVD or CD to live session registrations to share with colleagues. Learn more about collecting and assessing social determinants of health data in the primary care setting at http://store.hin.com/product.asp?itemid=5231 "HIN is extremely excited about this June 1 program, which will tap the expertise of developers of a leading SDOH assessment tool. As Medicare and other health management platforms urge the industry to promote social and physical environments conducive to optimal health, this is a prime opportunity for providers and payors to learn from AllianceChicago's SDOH assessment efforts across 38 FQHCs." -Melanie Matthews, HIN Executive VP and COO For Melanie Matthews's profile, please visit http://www.hin.com/bios.html#mm Please contact Patricia Donovan to arrange an interview or to obtain additional quotes. About the Healthcare Intelligence Network — HIN is the premier advisory service for executives seeking high-quality strategic information on the business of healthcare. For more information, contact the Healthcare Intelligence Network, PO Box 1442, Wall Township, NJ 07719-1442, (888) 446-3530, fax (732) 449-4463, e-mail info@hin.com, or visit http://www.hin.com. Sea Girt, NJ, May 22, 2017 --( PR.com )-- Since co-developing the social determinants of health (SDOH) assessment tool PRAPARE (Protocol for Responding to and Assessing Patient Assets, Risks and Experiences), AllianceChicago has deployed PRAPARE to 38 federally qualified health centers (FQHCs) for collection of SDOH data.During "Assessing Social Determinants of Health: Collecting and Responding to Data in the Primary Care Setting," a June 1, 2017 webinar at 1:30 p.m. Eastern, AllianceChicago will share key learnings from PRAPARE deployment and SDOH collection.Following this 45-minute live webcast, this Healthcare Intelligence Network program will be available in on-demand and recorded formats for educational and training purposes.Learn more about collecting and assessing social determinants of health data in the primary care setting at http://store.hin.com/product.asp?itemid=5231News Facts:Scheduled Speaker: Andrew Hamilton, RN, BSN, MS, chief informatics officer/deputy director, AllianceChicago.Conference Focus: The key details from AllianceChicago's PRAPARE deployment that addresses each FQHC's patient population, in-house staff and resources and community support. Mr. Hamilton will cover the following:- How organizations are collecting SDOH data...from assessment administration format to the timing and care team members participating in the collection—as well as the challenges, data collected and opportunities from various scenarios;- Prerequisite resources for healthcare providers embarking upon SDOH data collection;- Why staff training and buy-in is a critical aspect of SDOH data collection and the key training components;- How healthcare providers can react to SDOH data, including community resource referrals, healthcare action prescriptions, inclusion in longitudinal care plans and management of population health;- What technology is required to store and track SDOH data; and- The correlation of SDOH data collection and action on Hemoglobin A1C levels and asthma and blood pressure control.Ample time for Q&A will be provided.Webinar Formats: 45-minute live webinar on June 1, 2017 at 1:30 pm Eastern, including Q&A; "On-Demand" replay available June 2, 2017; 45-minute training DVD or CD-ROM with printed transcript available June 22, 2017. Participants may add an on-demand replay, DVD or CD to live session registrations to share with colleagues.Learn more about collecting and assessing social determinants of health data in the primary care setting at http://store.hin.com/product.asp?itemid=5231"HIN is extremely excited about this June 1 program, which will tap the expertise of developers of a leading SDOH assessment tool. As Medicare and other health management platforms urge the industry to promote social and physical environments conducive to optimal health, this is a prime opportunity for providers and payors to learn from AllianceChicago's SDOH assessment efforts across 38 FQHCs." -Melanie Matthews, HIN Executive VP and COOFor Melanie Matthews's profile, please visit http://www.hin.com/bios.html#mmPlease contact Patricia Donovan to arrange an interview or to obtain additional quotes.About the Healthcare Intelligence Network — HIN is the premier advisory service for executives seeking high-quality strategic information on the business of healthcare. For more information, contact the Healthcare Intelligence Network, PO Box 1442, Wall Township, NJ 07719-1442, (888) 446-3530, fax (732) 449-4463, e-mail info@hin.com, or visit http://www.hin.com. Click here to view the list of recent Press Releases from Healthcare Intelligence Network


Hires Expert FDA Device Submission Firm; Outlines In-Parallel FDA Data Collection Strategy; Expands Medical Advisory Board with Doctors from 2 Top Cancer Hospitals; Narrows Indication List from 18 to 6 KENNEWICK, WA / ACCESSWIRE / February 14, 2017 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a cancer therapeutics company focused on the commercialization of their RadioGel™ device, a tumor-injectable and biodegradable radiation that remains focused at the treatment site, today released a letter from its new President and CEO, Dr. Mike Korenko: With my first letter on January 11, I shared AMI's plans for our near-term future. With this letter, I will discuss the progress on that plan in the medical sector of our business over the last month. PATH FORWARD WITH THE FOOD AND DRUG ADMINISTRATION (FDA) In order to maximize our expertise in communicating with the FDA, I spent a lot of time locating the correct FDA expert to be at our side. We have engaged Hogan Lovells. They have 21 lawyers in the field of FDA devices and are very familiar with the personnel at the FDA. We are thrilled to have the input of senior partner John Smith, M.D., J.D. As both a physician and a lawyer, John combines clinical and regulatory experience relating to the FDA with a practical approach to addressing the regulatory issues. He places a particular focus on bringing device-based technologies to market. John and his lawyers have just completed the review of all our previous FDA communications and our supporting data. Based on their recommendations with respect to interacting with the FDA, we intend to: 1. Introduce AMI's new leadership and let them know we have listened; we are narrowing our indication for use to secure our first approval and completing the test plans to answer their previous questions for their review. 2. Present our specific test plans and data in a Pre-Submission meeting to clarify the final application. 4. With the FDA's permission, submit a de novo application for approval (FDA.gov De Novo Application FAQs). The FDA classification of RadioGel™ as a device increases our chances of a timely FDA approval exponentially. The critical path on the overall schedule to approval is, first, to complete laboratory testing concurrent with veterinary animal studies, then into human clinical trials. It is my intent to align the animal treatments in our veterinarian business division to support the animal testing required for the FDA to synergize the two divisions, and potentially create time and cost savings. In this parallel strategy, the company looks to move to first-in-man trials as soon as possible, while aggressively pursuing near-term revenues through the veterinary division, IsoPet, and through licensing. Our Medical Advisory Board has been expanded. Under the Chairmanship of Dr. Barry Pressman (a neuroradiology expert at Cedars-Sinai Medical Center in Los Angeles and Past-President of the American College of Radiology), the Board now includes Dr. Albert Denittis (Chief of Radiation Oncology Lankenau Medical Center), and Dr. Howard Sandlin (Ronald H. Bloom Chair in Cancer Therapeutics, Professor and Chair, Department of Radiation Oncology, Cedars-Sinai Medical Center). Their combined medical experience adds up to over 125 years. We have also been harvesting advice from other doctors, including two from the Mayo Clinic. The focus of the Advisory Boards is to prioritize our indications for use (which cancer types to treat first) in order to present them one at a time, in sequence to the FDA. The Board has selected 18 cancers that are good candidates for treatment with RadioGel™. To me, this large number is a confirmation of our belief that RadioGel has broad potential to treat a variety of tumors. From a business standpoint, it set the stage for incremental growth for many years into the future. In the near-term, we are prioritizing this list down to our top three therapy targets based on specific criteria. 1. Potential for FDA approval and successful therapy: a. Accessibility in the body, ease of application b. Therapeutic effectiveness in response to radiation c. Potential collateral risks from injection d. FDA Testing requirements 3. Business considerations a. Number of patients diagnosed yearly b. Ease of acceptance by the medical community c. Medical Insurance and Medicare reimbursement To paraphrase: 1) It works; 2) Nobody has a better mousetrap; and 3) It has to be profitable to the medical business sector. There have been other great products that made it through the FDA and failed, since the medical community did not see a profitable way to adapt the new technology. The medical community cares about saving lives, but they are in a business. We did not want to be surprised by that reality. As of today, we are down to six near-term candidates. We hope to have our final selection before the end of February. This is an important decision, so we need to get it right. I will send out another shareholder letter when we select our first indication for use. I will also discuss our veterinarian sector's business plan, as well as some updates in a near-term communication to you. I hope this was not too much detail, but I am not a big fan of fluff. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for cancer treatment. The IsoPet Solutions division is focused on utilizing RadioGel for a cancer therapy in animals. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales, and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our websites: www.isopetsolutions.com and www.isotopeworld.com. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners, and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control. Hires Expert FDA Device Submission Firm; Outlines In-Parallel FDA Data Collection Strategy; Expands Medical Advisory Board with Doctors from 2 Top Cancer Hospitals; Narrows Indication List from 18 to 6 KENNEWICK, WA / ACCESSWIRE / February 14, 2017 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a cancer therapeutics company focused on the commercialization of their RadioGel™ device, a tumor-injectable and biodegradable radiation that remains focused at the treatment site, today released a letter from its new President and CEO, Dr. Mike Korenko: With my first letter on January 11, I shared AMI's plans for our near-term future. With this letter, I will discuss the progress on that plan in the medical sector of our business over the last month. PATH FORWARD WITH THE FOOD AND DRUG ADMINISTRATION (FDA) In order to maximize our expertise in communicating with the FDA, I spent a lot of time locating the correct FDA expert to be at our side. We have engaged Hogan Lovells. They have 21 lawyers in the field of FDA devices and are very familiar with the personnel at the FDA. We are thrilled to have the input of senior partner John Smith, M.D., J.D. As both a physician and a lawyer, John combines clinical and regulatory experience relating to the FDA with a practical approach to addressing the regulatory issues. He places a particular focus on bringing device-based technologies to market. John and his lawyers have just completed the review of all our previous FDA communications and our supporting data. Based on their recommendations with respect to interacting with the FDA, we intend to: 1. Introduce AMI's new leadership and let them know we have listened; we are narrowing our indication for use to secure our first approval and completing the test plans to answer their previous questions for their review. 2. Present our specific test plans and data in a Pre-Submission meeting to clarify the final application. 4. With the FDA's permission, submit a de novo application for approval (FDA.gov De Novo Application FAQs). The FDA classification of RadioGel™ as a device increases our chances of a timely FDA approval exponentially. The critical path on the overall schedule to approval is, first, to complete laboratory testing concurrent with veterinary animal studies, then into human clinical trials. It is my intent to align the animal treatments in our veterinarian business division to support the animal testing required for the FDA to synergize the two divisions, and potentially create time and cost savings. In this parallel strategy, the company looks to move to first-in-man trials as soon as possible, while aggressively pursuing near-term revenues through the veterinary division, IsoPet, and through licensing. Our Medical Advisory Board has been expanded. Under the Chairmanship of Dr. Barry Pressman (a neuroradiology expert at Cedars-Sinai Medical Center in Los Angeles and Past-President of the American College of Radiology), the Board now includes Dr. Albert Denittis (Chief of Radiation Oncology Lankenau Medical Center), and Dr. Howard Sandlin (Ronald H. Bloom Chair in Cancer Therapeutics, Professor and Chair, Department of Radiation Oncology, Cedars-Sinai Medical Center). Their combined medical experience adds up to over 125 years. We have also been harvesting advice from other doctors, including two from the Mayo Clinic. The focus of the Advisory Boards is to prioritize our indications for use (which cancer types to treat first) in order to present them one at a time, in sequence to the FDA. The Board has selected 18 cancers that are good candidates for treatment with RadioGel™. To me, this large number is a confirmation of our belief that RadioGel has broad potential to treat a variety of tumors. From a business standpoint, it set the stage for incremental growth for many years into the future. In the near-term, we are prioritizing this list down to our top three therapy targets based on specific criteria. 1. Potential for FDA approval and successful therapy: a. Accessibility in the body, ease of application b. Therapeutic effectiveness in response to radiation c. Potential collateral risks from injection d. FDA Testing requirements 3. Business considerations a. Number of patients diagnosed yearly b. Ease of acceptance by the medical community c. Medical Insurance and Medicare reimbursement To paraphrase: 1) It works; 2) Nobody has a better mousetrap; and 3) It has to be profitable to the medical business sector. There have been other great products that made it through the FDA and failed, since the medical community did not see a profitable way to adapt the new technology. The medical community cares about saving lives, but they are in a business. We did not want to be surprised by that reality. As of today, we are down to six near-term candidates. We hope to have our final selection before the end of February. This is an important decision, so we need to get it right. I will send out another shareholder letter when we select our first indication for use. I will also discuss our veterinarian sector's business plan, as well as some updates in a near-term communication to you. I hope this was not too much detail, but I am not a big fan of fluff. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for cancer treatment. The IsoPet Solutions division is focused on utilizing RadioGel for a cancer therapy in animals. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales, and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our websites: www.isopetsolutions.com and www.isotopeworld.com. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners, and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.


Research and Markets has announced the addition of the "Virtual Reality for Consumer Markets" report to their offering. Industry players continue fine-tuning their products so as not to muddy the water for all involved. It is believed that these efforts will bear fruit in the coming years, and that combined revenue for head-mounted displays (HMDs), VR accessories, and VR content will increase from $453.6 million in 2015 to $35.0 billion worldwide in 2021, representing a compound annual growth rate (CAGR) of 133%. The year 2016 will be remembered as the debut of consumer virtual reality (VR), with key ambassadors in the form of Facebook/Oculus, HTC/Valve, Sony, Samsung, and a collective community of companies in China planting their stakes in the ground with formidable investments in jumpstarting a new computing platform. After a shaky start, Facebook's Oculus Rift and HTC/Valve's VIVE started selling in the U.S. in 3Q 2016 and are stabilizing their ecosystems and distribution in 4Q 2016, as they are joined by Sony with the debut of PlayStation VR. A number of lessons have been learned since the 1990s when consumer VR last generated this much hype, with huge strides having been made in terms of creating compelling content and a convincing level of immersion. Getting users to experience VR technology firsthand, and therefore truly understand its potential, remains a challenge, but the emergence of low-cost mobile VR solutions is helping. Even so, some industry participants strongly believe that anything requiring the user to wear a cumbersome device will ultimately fail. The stakes are high given the huge amount of money invested in the industry by some of the world's biggest companies. This report provides a comprehensive analysis of the market dynamics, technology issues, and competitive landscape for consumer VR HMDs, accessories, and content. The report features global market forecasts for annual unit shipments and associated revenue during the period from 2014 through 2021, segmented by five world regions. HMDs are segmented into four product types: PC-based devices, console-based devices, all-in-one devices, and mobile VR headsets. VR accessories, such as gamepads and other VR-specific controllers, hand tracking devices, and 360° cameras are also quantitatively analyzed. The content market is segmented into gaming and media. - How large is the market opportunity for consumer VR hardware and content? - How will the market be segmented by product type, content type, and world region? - How will this market grow in the coming years and which factors will drive this growth? - Which factors could inhibit growth during the forecast period? - What are the main technology trends and issues in the consumer VR market? - Who are the leading providers of consumer VR technology and how do their go-to-market strategies differ? 2. Market Issues 2.1. Introduction 2.2. Scope of Study 2.2.1. Consumer VR Hardware Scope 2.3. Market Overview 2.4. Market Trends 2.5. Market Drivers 2.5.1. Immersion Experiences 2.5.2. Games Market 2.5.3. Three-Dimensional User Interface 2.5.4. User Interface Shift to Hands/Gesture Control 2.5.5. Smartphone Upgrades 2.5.6. Personal Computer Upgrades 2.5.7. China 2.5.8. VR Video 2.5.9. Mobile Ecosystem/App Stores 2.5.10. Web VR 2.5.11. Cloud Gaming 2.6. Market Barriers 2.6.1. Cost 2.6.2. Complex, Multi-Element Purchase 2.6.3. Quality of Experience 2.6.3.1. Virtual Reality Sickness 2.6.3.2. Restricted Field of View 2.6.3.3. Tethering 2.6.3.4. Lack of Natural User Input 2.6.3.5. Streaming Challenges 2.6.3.6. Corrective Eyewear 2.6.4. Trial and Error for Early Virtual Reality Applications 2.7. Use Cases 2.7.1. Games 2.7.2. Video Media Content 2.7.3. Social VR 2.7.4. Marketing 2.7.4.1. Retail E-Commerce 2.7.4.2. Residential Buying/Renting 2.7.4.3. Travel 2.7.5. Wellness Self Help 2.7.6. Fitness 2.7.7. Spatial Computing 3. Technology Issues 3.1. Introduction 3.2. Tracking 3.2.1. Inside-Out and Outside-In 3.2.1.1. Simultaneous Location and Mapping and Computer Vision 3.2.2. Eye Tracking 3.2.3. Hand Tracking Solutions 3.2.4. Gesture Control 3.3. Field of View 3.4. Latency Technologies and Virtual Reality Sickness Prevention 3.4.1. Galvanic Vestibular Stimulation 3.4.2. Frame Tearing 3.4.2.1. Oculus Asynchronous Timewarp and Spacewarp 3.4.2.2. VIVE Asynchronous Reprojection 3.4.3. Field of View Restrictors 3.5. Display Technology 3.6. Graphics Processing Units 3.7. Cameras 3.8. Three-Dimensional Audio 3.9. Adaptive Streaming 3.9.1. Bitmovin 3.9.2. Pixvana 3.10. Seated versus Moving Experiences 3.10.1. Wireless Connectivity Technologies 3.10.2. Local Rendering 4. Key Industry Players 4.1. Introduction 4.2. Key Head-Mounted Display and Platform Players 4.2.1. HTC 4.2.2. Facebook 4.2.2.1. Content Initiatives 4.2.2.2. Evolving Head-Mounted Displays and Virtual Reality Experience 4.2.2.3. Social Virtual Reality 4.2.3. Sony 4.2.4. Google 4.2.5. Microsoft 4.2.6. Razer 4.2.7. Starbreeze Studios and Acer 4.2.8. NVIDIA 4.2.9. Sulon Technologies 4.3. Key Enabling Technology Players 4.3.1. VisiSonics 4.3.2. Bitmovin 4.3.3. Pixvana 4.3.4. uSens 4.3.5. Leap Motion 4.3.6. vMocion 4.3.7. Binary VR 4.3.8. Improbable 4.3.9. Movidius 4.3.10. VR Lens Lab 4.4. Other Key Players 4.4.1. Vroom 4.4.2. Alibaba 4.4.3. Amazon 4.4.4. NextVR 4.4.5. Wevr 4.4.6. Baobab Studios 4.4.7. Surreal VR 4.4.8. AltspaceVR 4.4.9. nDreams 4.4.10. Unity Technologies 4.4.11. Machina OBE 4.5. Other Selected Industry Participants 5. Market Forecasts 5.1. Introduction 5.2. Data Collection 5.3. Forecast Methodology 5.3.1. Top-Level Head-Mounted Display Shipments 5.3.2. Virtual Reality Accessories 5.3.3. Average Selling Prices and Revenue 5.4. Virtual Reality Mass Market Penetration Estimates 5.5. Top-Level Annual Virtual Reality Revenue 5.6. Annual Virtual Reality Head-Mounted Display Shipments and Revenue 5.7. Annual Virtual Reality Accessories Shipments and Revenue 5.8. Annual Virtual Reality Content Revenue by Content Type 5.9. Consumer Virtual Reality Market by Region 5.10. Conclusions and Recommendations For more information about this report visit http://www.researchandmarkets.com/research/zh6t3m/virtual_reality


News Article | February 17, 2017
Site: www.eurekalert.org

Reno, Nev. (Feb. 16, 2017) - Nevada's unmanned cloud-seeding research team has realized another fundamental capability in their effort toward enhancing snowfall in mountainous regions of the West. Flown at Hawthorne Industrial Airport under Nevada UAS Test Sites Certificate of Authorization (COA) and led by the Desert Research Institute (DRI) flight operations node, the Drone America Savant unmanned, fixed-wing aircraft reached an altitude of 1,500 feet and completed a one-hour BVLOS flight covering a total distance of 28 nautical miles on Wednesday, February 15, 2017. The test flight of the Savant cloud-seeding aircraft was the longest unmanned, cross-country round-trip flight in Nevada history. Beyond Visual Line of Sight (BVLOS) describes an aviation event in which the unmanned aircraft flies autonomously over a long distance. Flight crew members control and track the aircraft in real-time using computer-aided controls, but the pilot is not capable of visually following the aircraft during flight with the naked eye. "We have now demonstrated without a doubt that our unmanned cloud seeding technology and capabilities can move beyond line of sight - a significant hurdle in this industry," said Adam Watts, Ph.D., principal investigator on the project and an assistant research professor at DRI. "Most importantly, we have done this safely and in following all FAA regulations and guidelines." For more than a year a DRI-led research team, supported by the Nevada Governor's Office of Economic Development through the Knowledge Fund, has been working to develop an unmanned cloud seeding aircraft capable of helping communities address the ongoing impacts of drought and explore innovative solutions for natural-resource challenges such as augmenting regional water supplies. The research team combines more than 30 years of weather modification research and expertise at DRI with the proven experience in aerospace manufacturing and flight operations of Reno-based Drone America, and the industry leading unmanned aerial data services of Las Vegas-based AviSight. "Reaching this milestone allows us to now focus on higher altitude, longer distance flights; as well as the extreme challenges of flying our advanced unmanned fixed-wing aircraft in the harsh, icy weather that come with optimal winter cloud-seeding conditions," said Mike Richards, President and CEO of Drone America. The field operation was supported by multiple ground-based safety officials and visual observers. "Hawthorne offers an ideal location for BVLOS testing for both small and large UAS (greater than 55 pounds)," said Chris Walach, Ph.D., Director of the FAA-designated Nevada UAS Test Site. "And, when combined with the NASA tested BVLOS drone flights at one of the Nevada UAS Test Sites late last year, this again demonstrates Nevada's foremost capability to lead and support the nation's UAS industry and help advance BVLOS techniques and procedures that can eventually lead to safely integrating unmanned aircraft into the national airspace." For more information on DRI's unmanned cloud seeding project and UAS industry support visit - http://www. Additional photos and video available upon request. About the Desert Research Institute: DRI, the nonprofit research arm of the Nevada System of Higher Education, is a world leader in environmental sciences through the application of knowledge and technologies to improve people's lives throughout Nevada and the world. For more information about DRI please visit http://www. About Drone America: Drone America strives to be one of the World's Top Providers of Autonomous Unmanned Vehicles, high tech equipment and services. Our mission is to use UAS technologies as a means to survey, protect, and preserve human life and strategic resources around the Globe. For more information about Drone America please visit http://www. About AviSight: AviSight is an aerospace and remote sensing services company based in Las Vegas, Nevada. Our company employs Aerospace systems, Remote Sensing technology, Analytics, and Data Collection/Distribution systems for commercial and government clients. For more information about AviSight please visit http://www. About the Nevada Institute for Autonomous Systems (NIAS): The Nevada Institute for Autonomous Systems (NIAS) and FAA-designated Nevada Unmanned Aviation Test Site leads the growth of the Nevada Unmanned Aviation Systems (UAS) Industry through business teaming relationships, collaborating with primary research institutions on UAS research and development, and enhancing the Nevada UAS Industry knowledge base to attract new and permanent business and create jobs in the State of Nevada. Learn more at http://www. .


News Article | February 17, 2017
Site: globenewswire.com

RENO, Nev., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Nevada's unmanned cloud-seeding research team has realized another fundamental capability in their effort toward enhancing snowfall in mountainous regions of the West. Flown at Hawthorne Industrial Airport under Nevada UAS Test Sites Certificate of Authorization (COA) and led by the Desert Research Institute (DRI) flight operations node, the Drone America Savant™ unmanned cloud-seeding aircraft reached an altitude of 1,500 feet and completed a one-hour BVLOS flight covering a total distance of 28 nautical miles on Wednesday, February 15, 2017. The test flight of the Savant™ cloud-seeding aircraft was the longest unmanned, cross-country round-trip flight in Nevada history. Beyond Visual Line of Sight (BVLOS) describes an aviation event in which the unmanned aircraft flies autonomously over a long distance. Flight crew members control and track the aircraft in real-time using computer-aided controls, but the pilot is not capable of visually following the aircraft during flight with the naked eye. "We have now demonstrated without a doubt that our unmanned cloud seeding technology and capabilities can move beyond line of sight – a significant hurdle in this industry," said Adam Watts, Ph.D., principal investigator on the project and an assistant research professor at DRI. "Most importantly, we have done this safely and in following all FAA regulations and guidelines." For more than a year a DRI-led research team, supported by the Nevada Governor's Office of Economic Development through the Knowledge Fund, has been working to develop an unmanned cloud seeding aircraft capable of helping communities address the ongoing impacts of drought and explore innovative solutions for natural-resource challenges such as augmenting regional water supplies. The research team combines more than 30 years of weather modification research and expertise at DRI with the proven experience in aerospace manufacturing and flight operations of Reno-based Drone America, and the industry leading unmanned aerial data services of Las Vegas-based AviSight. "Reaching this milestone allows us to now focus on higher altitude, longer distance flights; as well as the extreme challenges of flying our advanced unmanned fixed-wing aircraft in the harsh, icy weather that come with optimal winter cloud-seeding conditions," said Mike Richards, President and CEO of Drone America. The field operation was supported by multiple ground-based safety officials and visual observers. "Hawthorne offers an ideal location for BVLOS testing for both small and large UAS (greater than 55 pounds)," said Chris Walach, Ph.D., Director of the FAA-designated Nevada UAS Test Site. "And, when combined with the NASA tested BVLOS drone flights at one of the Nevada UAS Test Sites late last year, this again demonstrates Nevada's foremost capability to lead and support the nation's UAS industry and help advance BVLOS techniques and procedures that can eventually lead to safely integrating unmanned aircraft into the national airspace." For more information on DRI's unmanned cloud seeding project and UAS industry support visit – www.dri.edu Photo Caption: The Drone America Savant™ unmanned fixed-wing aircraft during its historic 28 nautical-mile BVLOS flight on Wednesday, February 15, 2017. Credit: Zach Clark/Drone America Additional photos and video available upon request. About the Desert Research Institute: DRI, the nonprofit research arm of the Nevada System of Higher Education, is a world leader in environmental sciences through the application of knowledge and technologies to improve people's lives throughout Nevada and the world. For more information about DRI please visit www.dri.edu About Drone America: Drone America strives to be one of the World's Top Providers of Autonomous Unmanned Vehicles, high tech equipment and services. Our mission is to use UAS technologies as a means to survey, protect, and preserve human life and strategic resources around the Globe. For more information about Drone America please visit www.droneamerica.com/ About AviSight: AviSight is an aerospace and remote sensing services company based in Las Vegas, Nevada. Our company employs Aerospace systems, Remote Sensing technology, Analytics, and Data Collection/Distribution systems for commercial and government clients. For more information about AviSight please visit www.avisight.com/ About the Nevada Institute for Autonomous Systems (NIAS): The Nevada Institute for Autonomous Systems (NIAS) and FAA-designated Nevada Unmanned Aviation Test Site leads the growth of the Nevada Unmanned Aviation Systems (UAS) Industry through business teaming relationships, collaborating with primary research institutions on UAS research and development, and enhancing the Nevada UAS Industry knowledge base to attract new and permanent business and create jobs in the State of Nevada. Learn more at www.nias-uas.com. For additional photos and b-roll media contacts are: Justin Broglio Communications Officer, Desert Research Institute Ph: (775) 673-7610 media@dri.edu Mark Barker  Director of Business Development and Marketing, the FAA-designated Nevada UAS Test Site and the Nevada Institute for Autonomous Systems (NIAS)  Ph: (702) 793-4218  Mark.Barker@nias-uas.com Photos accompanying this release are available at: http://www.globenewswire.com/newsroom/prs/?pkgid=42193 http://www.globenewswire.com/newsroom/prs/?pkgid=42194


News Article | February 15, 2017
Site: www.marketwired.com

SASKATOON, SASKATCHEWAN--(Marketwired - Feb. 14, 2017) - International Road Dynamics Inc. (TSX:IRD) announced today that the New York State Department of Transportation (NYSDOT) has awarded the Company a five-year Traffic Data Collection Installation and Maintenance contract valued at USD $7.34 million. Under this agreement, IRD will install, upgrade, repair, operate, and maintain permanently installed traffic data collection sites located within the state of New York. There are six types of Traffic Data Collection sites covered under this contract, including Continuous Count (CC), Automatic Vehicle Classification (AVC), Weigh-in-Motion (WIM), Permanent Short Count (PSC), Wireless Vehicle Detection Systems, and Shared Traffic Data Collection Sites. The NYSDOT uses these sites to collect, summarize, and interpret information about the traffic traveling on the State's highways system. The data is required to assess transportation needs and infrastructure performance, as well as to develop planning and programming recommendations. "We are pleased to receive this long term commitment to provide installation and maintenance services to the State of New York. This agreement complements the award IRD previously obtained for permanent traffic data collection maintenance and upgrades within New York City and Long Island," commented Terry Bergan, IRD's President and CEO. "Contracts such as this add to our recurring revenues and align with our corporate strategy to pursue growth in our expanding Maintenance and Data Services business." IRD is a highway traffic management technology company specializing in supplying products and systems to the global Intelligent Transportation Systems (ITS) industry. IRD is a North American company based in Saskatoon, Saskatchewan Canada with sales and service offices throughout the United States and overseas. Private corporations, transportation agencies and highway authorities around the world use IRD's products and advanced systems to manage and protect their highway infrastructures. The Company's shares trade on the Toronto Stock Exchange under the symbol IRD. IRD is listed on the TSX - trading symbol - IRD


News Article | February 15, 2017
Site: www.businesswire.com

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Qualitative Research in Political Science" book to their offering. In recent years there has been an explosion of research on qualitative methodology and methods in the social sciences at large, and in the field of Political Science in particular. This Major Work presents a comprehensively curated collection of key literature on this subject, organised into four thematic volumes: Volume One includes papers on the ontological and epistemological foundations of qualitative research, before moving onto articles that compare qualitative with quantitative research, as well as statements that contrast the divergent strands within qualitative research. Volume Two includes literature that exemplifies the tradition and techniques of cross-case comparisons. Volume Three is devoted to the spectrum of approaches that focuses on within-case analysis in order to provide evidence for causal claims. The selected works shed light on the corresponding major concepts: causal mechanisms, congruence and process tracing. Volume Four captures the spectrum of qualitative methods that highlights the importance of context and social constructions (meanings) and is most often summed up as interpretivism: ethnographic and practice approaches as well as discourse, frame and narrative analysis. VOLUME ONE: BACKGROUNDS, PATHWAYS AND DIRECTIONS IN QUALITATIVE METHODOLOGY Part One: The Revolt in the US: Alternatives to the Statistical Template Part Two: Building on and Defending European Traditions: From Verstehen to Practice and Interpretation Part Four: Concept Building as the Analytic Path for Connecting Description and Meaning Part Five: The Call for Transparency: Rigor and/or Reflexivity in Data Collection/Creation For more information about this book visit http://www.researchandmarkets.com/research/jswk2g/qualitative


News Article | February 26, 2017
Site: www.prnewswire.com

Rugged, Versatile Platform Is Designed For Aerial Inspection And Data Collection BARCELONA, Spain, Feb. 26, 2017 /PRNewswire/ -- DJI, the world leader in unmanned aerial technology, Sunday unveiled the new Matrice 200 drone series (M200), which is purpose-built for professional users...


News Article | February 28, 2017
Site: www.PR.com

Receive press releases from Strathmore Who's Who: By Email Deborah J. Callender Has Recently Been Recognized by Strathmore’s Who’s Who Deborah J. Callender, of Carriere, Mississippi has recently been recognized as a 2017 Professional of the Year by Strathmore’s Who’s Who for her outstanding contributions and achievements in field of Government Sciences and Oceanographic Research. Deborah J. Callender is a Physical Scientist with the Naval Oceanographic Office. Ms. Callender received a B.A. in English from the University of Utah, an M.A. in Management from the University of Redlands, and an M.S. in 3D and Virtual Reality Imaging from the University of Southern Mississippi. Ms. Callender’s field of expertise is Geospatial Analysis, Program/Project Management, and Marine Environmental Data Collection and Analysis. She is a member of AAG, AGU, AMS, and IWLA. About Strathmore’s Who’s Who Strathmore's Who's Who publishes an annual two thousand page hard cover biographical registry, honoring successful individuals in the fields of Business, the Arts and Sciences, Law, Engineering and Government. Based on one's position and lifetime of accomplishments, we honor professional men and women in all academic areas and professions. Inclusion is limited to individuals who have demonstrated leadership and achievement in their occupation, industry or profession. Carriere, MS, February 28, 2017 --( PR.com )-- About Deborah J. CallenderDeborah J. Callender is a Physical Scientist with the Naval Oceanographic Office. Ms. Callender received a B.A. in English from the University of Utah, an M.A. in Management from the University of Redlands, and an M.S. in 3D and Virtual Reality Imaging from the University of Southern Mississippi. Ms. Callender’s field of expertise is Geospatial Analysis, Program/Project Management, and Marine Environmental Data Collection and Analysis. She is a member of AAG, AGU, AMS, and IWLA.About Strathmore’s Who’s WhoStrathmore's Who's Who publishes an annual two thousand page hard cover biographical registry, honoring successful individuals in the fields of Business, the Arts and Sciences, Law, Engineering and Government. Based on one's position and lifetime of accomplishments, we honor professional men and women in all academic areas and professions. Inclusion is limited to individuals who have demonstrated leadership and achievement in their occupation, industry or profession. Click here to view the list of recent Press Releases from Strathmore Who's Who

Loading Data Collection collaborators
Loading Data Collection collaborators